CA19-9 as a Marker for Ovarian Cancer
Author Information
Author(s): P.A. Canney, P.M. Wilkinson, R.D. James, M. Moore
Primary Institution: Christie Hospital and Holt Radium Institute
Hypothesis
Can CA19-9 levels in serum provide more information about ovarian carcinoma compared to CA125 levels?
Conclusion
CA19-9 is not adequate as a standalone marker for ovarian cancer but may provide additional prognostic information when used alongside CA125.
Supporting Evidence
- CA19-9 levels were measured in patients with known ovarian carcinoma.
- The overall sensitivity for CA125 was 76%, while the combined sensitivity with CA19-9 rose to 80%.
- Elevated CA19-9 levels before chemotherapy were associated with a significant adverse prognosis.
Takeaway
This study looked at a blood test called CA19-9 to see if it helps find ovarian cancer better than another test called CA125. It found that CA19-9 isn't good enough on its own but can give extra information when used with CA125.
Methodology
Sera from 55 patients with ovarian adenocarcinoma were tested for CA19-9 and CA125 levels using radioimmunoassays.
Limitations
The sensitivity of the CA19-9 assay was low at 29%, making it inadequate as a standalone marker.
Participant Demographics
Patients with histologically proven ovarian adenocarcinoma.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website